Allergen immunotherapy: Therapeutic vaccines for allergic diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 53, Issue SUPPL. 44, 1998, Pages 1-42

  Bousquet, Jean ^a   Lockey, Richard F ^a   Malling, Hans Jorgen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANT VENOM; BEE VENOM; VACCINE; WASP VENOM; ADRENALIN; ALLPYRAL; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONJUVAC; CORTICOSTEROID; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; HYPERTENSIVE AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFUSION FLUID; PLACEBO;

ANIMAL; CHILD; COST CONTROL; DESENSITIZATION; FORECASTING; HUMAN; HYPERSENSITIVITY; METHODOLOGY; PRESCHOOL CHILD; REVIEW; RISK FACTOR; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; AQUEOUS SOLUTION; ASTHMA; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EFFECTOR CELL; FATALITY; GOOD MANUFACTURING PRACTICE; GRASS POLLEN; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAGWEED POLLEN; STANDARDIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; VACCINATION; VACCINE PRODUCTION;

ALLERGENS; ANIMALS; ANT VENOMS; BEE VENOMS; CHILD; CHILD, PRESCHOOL; COST CONTROL; DESENSITIZATION, IMMUNOLOGIC; FORECASTING; HUMANS; HYPERSENSITIVITY; RISK FACTORS; VACCINES; WASP VENOMS;

EID: 0031817107     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1998.tb04930.x     Document Type: Article

References (422)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.
2. Current status of allergen immunotherapy (hyposensitisation). Report of a WHOIIUIS working group. Allergy 1989;44:369-79.
3. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet 1989;1:259-61.
4. Mailing H-J, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology. Allergy 1993;48 Suppl 14:9-35.
5. Bousquet J, Muller UR, Dreborg S, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergology and Clinical Immunology. Allergy 1987;42: 401-13.
6. Muller U, Mosbech H. Immunotherapy with Hymenoptera venoms. Position paper. Allergy 1993;48 Suppl 14:37-46.
7. International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy 1992;47:1-61.
8. Global strategy for asthma management and prevention. WHOINHLBI workshop report. In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication no. 95-3659, 1995.
9. International Consensus Report on Diagnosis and Management of Rhinitis. Allergy 1994;49 Suppl 19:1-33.
10. Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ 1993;307:919-23.
11. Nicklas R, Bernstein I, Blessing-Moore J, et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;6:1001-11.
12. Biological products: allergenic extracts: implementation of efficacy review. Federal Register, Food and Drug Administration, 1985;21 CRF Parts 600, 610 and 680 [Docket no. 81N-00961.]
13. Allergen products (Producta allergenica). European Pharmacopeia, 1997:1063-8.
14. Dreborg S, Frew A. Allergen standardization and skin tests. EAACI Position paper. Allergy 1993;48 Suppl 14:49-82.
15. The use of standardized allergen extracts. Position Statement. American Academy of Allergy, Asthma, and Immunology (AAAAI). J Allergy Clin Immunol 1997;99: 5 83-6.
16. Rules governing medicinal products in the European Community. Vol. III. Note for guidance on allergen products. CPMP/BWP/243!96, 1991.
17. Løwenstein H. Report on behalf of the International Union of Immunological Societies (l.U.I.S.) Allergen Standardization Subcommittee. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1983;78:41-8.
18. Nordic Council on Medicines. Registration of allergen preparations, 2nd ed. Nordiska Lakemedelsnamnden. NLN Publication no. 23, Uppsala, 1989.
19. Løwenstein H. Report on behalf of the International Union of Immunological Societies (I.U.I.S.) Allergen Standardization Subcommittee. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1983;78:41-8.
20. Gjesing B, Jager L, Marsh DG, Løwenstein H. The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. J Allergy Clin Immunol 1985;75: 258-67.
21. Larsen JN, Ford A, Gjesing B, et al. The collaborative study of the international standard of dog, Canis domesticus, hair! dander extract. J Allergy Clin Immunol 1988;82:318-30.
22. Helm RM, Gauerke MB, Baer H, et al. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 1984; 73:790-800.
23. Helm RM, Squillace DL, Aukrust L, et al. Production of an international reference standard Alternaria extract. I. Testing of candidate extracts. Int Arch Allergy Appi Immunol 1987;82:178-89.
24. Platts-Mills TAE, Chapman MD. Allergen standardization. J Allergy Clin Inimunol 1991;87:621-5.
25. Norman PS. WHO-IUIS International Standards: advantages of these extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:59-64.
26. Mohapatra SS. Recombinant allergens and allergen standardization. J Allergy Clin Immunol 1992;89:921-2.
27. Kraft D, Sehon A. Molecular biology and immunology of allergens. Boca Raton, FL: CRC Press, 1992.
28. Bousquet J. Clinical use of recombinant allergens and epitopes. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:257-62.
29. Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose- response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol 1982; 70:343-52.
30. Bousquet J, Guerin B, Michel FB. Units of allergen extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1992;85:105-16.
31. Gleich G, Larson J, Jones R, Baer H. Measurement of the potency of allergy extracts by their inhibitory capacities in the radioallergosorbent test. J Allergy Clin Allergol 1974; 53: 158-69.
32. Maasch HJ, Wihi JA, Schultze-Werninghaus G, Geissler W, Wahl R. A manufacturer's criteria for in-house reference preparations for RAST inhibition. Ann Allergy 1987;59: 29-33.
33. Liu DT. Regulation of allergenic products in the U.S.A.: CBER initiatives. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:8-12.
34. Bousquet J, Michel F. Standardization of allergens. In: Spector S, editor. Provocation testing in clinical practice. New York: Marcel Dekker, 1994:15-50.
35. Schemer o, Kraft D. Basic and practical aspects of recombinant allergens. Allergy 1 995;50:384-92.
36. Chapman M. Monoclonal antibody immunoassays: quantitative methods for allergen standardization. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994; 87:120-4.
37. van Ree R. Analytical aspects of standardization of allergenic extracts. Allergy 1997;52:795-806.
38. Allergen nomenclature. WHO/IUS Allergen Nomenclature Subcommittee World Health Organization, Geneva, Switzerland. Clin Exp Allergy 1995;25:27-37.
39. King TP, Hoffman D, Lowenstein H, Marsh DG, PlattsMills TA, Thomas W. Allergen nomenclature. Allergy 1995; 50:765-74.
40. Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frank A M 1994;87:155-64.
41. Dreborg S, Einarsson R. The major allergen content of allergenic preparations reflects their biological activity. Allergy 1992;47:418-23.
42. Yasueda H. Okuda M, Yoshida H, et al. A basic policy for allergen standardization in our country and standardization of Japanese cedar (Cryptomeria japonica) pollen extracts. Allergen Committee in Japanese Society of Allergology. Allergol Tnt 1997;in press.
43. Steinberger P, Kraft D, Valenta R. Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. J Biol Chem 1996;271:10967-72.
44. Norman PS. International units. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1.988;82:45-9.
45. Turkeltaub PC. Use of skin testing for evaluation of potency, composition, and stability of allergenic products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:79-87.
46. Methods of Allergenic Products Testing Laboratory. CBER FDA Docket no. 94N-0012 1993.
47. Reisman RE, Arbesman CE, Lazell M. Clinical and immunological studies of venom immunotherapy. Clin Allergy 1979;9:167-74.
48. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61.
49. Yunginger JW, Paull BR, Jones RT, Santrach PJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol 1979;63:340-7.
50. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76: 734-44.
51. Bousquet J, Hejjaoui A, Skassa-Brociek W, et aT. Double- blind, placebo-controlled immunotherapy with mixed grass- pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-8.
52. Hedlin G, Graff-Lonnevig V, Heilbom H, et al. Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double- blind placebo study. J Allergy Clin Immunol 1986;77: 488-96.
53. Kordash TR, Amend MJ, Freshwater LL, Baker RE. In vivo and in vitro characterization of Alipyral grass pollen extracts. Ann Allergy 1994;73:127-33.
54. Warner JO, Price JF, Soothill IF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912-15.
55. Blainey A, Phillips M, Oilier S, Davies R. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial allergic rhinitis. Allergy 1984;39:521-8.
56. Genin I, Barratt G, Tran XT, Delattre J, Puisieux F Optimization and characterization of freeze-dried multilamellar liposomes incorporating different standardized allergen extracts. Allergy 1994;49:645-52.
57. Walls AF. Liposomes for allergy immunotherapy? Clin Exp Allergy 1992;22:1-2.
58. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen ailergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449-59.
59. Bousquet J, Maasch HI, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass- pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjurictivitis and asthma. J Allergy Clin Immunol 1989;84: 546-56.
60. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397-401.
61. Corrado OJ, Pastorello E, Ollier S, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. I. Clinical aspects. Allergy 1989;44:108-15.
62. Bousquet J, Michel PB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf 1994;l0:5-17.
63. Juniper EF, Roberts RS, Kennedy LK, et al. Polyethylene glycol-modified ragweed pollen extract in rhinoconjunctivitis. J Allergy Clin Immunol 1985;75:578-85.
64. Juniper EF, O'Connor 3, Roberts RS, Evans S, Hargreave FE, Dolovich J. Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens. J Allergy Clin Immunol 1986;78:851-6.
65. Muller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S. Lanner A. A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987;80:252-61.
66. Dreborg S, Akerblom EB. Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst 1990;6:315-65.
67. Mosbech H, Dreborg 5, Frolund L, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 1989;44:487-98.
68. Cockcroft D, Cuff M, Tarlo S, Dolovich J, Hargreave F. Allergen-injection therapy with glutaraldehyde-modifiedragweed pollen-tyrosine adsorbate. A double-blind trial. J Allergy Clin Immunol 1977;60:56-62.
69. Miller A. A trial of hyposensitization in 1974/5 in the treatment of hay fever using a glutaraldehyde-pollentyrosine adsorbate. Clin Allergy 1979;6:557-61.
70. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 1990;85:606-11.
71. Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts. J Allergy Clin Immunol 1981;67:64-9.
72. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:382-8.
73. Esch RE. Role of proteases on the stability of allergenic extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1992;85:171-7.
74. Kordash TR, Amend MI, Williamson SL, Jones 3K, Plunkett GA. Effect of mixing allergenic extracts containing Helminthosporium, D. farinae, and cockroach with perennial ryegrass. Ann Allergy 1993;71:240-6.
75. Frostad AB, Grimmer 0, Sandvik L, Moxnes A, Aas K. Clinical effects of hyposensitization using a purified allergen preparation from timothy pollen as compared to crude aqueous extracts from timothy pollen and a four-grass pollen mixture respectively. Clin Allergy 1983;13:337-57.
76. Moller C, Dreborg S. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results. Clin Allergy 1986;16:135-43.
77. Wihl jA, Ipsen H, Petersen BN, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double- blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43:363-9.
78. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
79. Shirakawa T, Enomoto T, Shimazu S, Hopkin M. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
80. Pene J, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2, Proc NatI Acad Sci U S A 1988;85:6880-4.
81. Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988;140: 4193-8.
82. de Vries JE, Zurawski G. Immunoregulatory properties of IL-13: its potential role in atopic disease. Tnt Arch Allergy Immunol 1995;106:175-9.
83. Yssel H, Fasler S, de Vries JE, de Waal-Malefyt R. IL-12 transiently induces IFN-gamma transcription and protein synthesis in human CD4+ allergen-specific Th2 T cell clones. mt Immunol 1994;6:1091-6.
84. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young O, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219-24.
85. Lichtenstein L, Ishizaka K, Norman P, Sobotka A, Hill B. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-82.
86. Gleich O, Zimmermann EM, Henderson LL, Yunginger JW Effect of immunotherapy on immunoglobulin F and immunoglobulin G antibodies to ragweed antigens: a six- year prospective study. J Allergy Clin Immunol 1982; 70:261-71.
87. Malling H-I, Skov PS, Permin H, Norn S. Weeke B. Basophil histamine release and humoral changes during immunotherapy. Dissociation between basophil-bound specific IgE, serum value, and cell sensitivity. Allergy 1982;37:187-90.
88. MacDonald SM, Rafnar T, Langdon I, Lichtenstein LM. Molecular identification of an IgE-dependent histamine- releasing factor. Science 1995;269:688-90.
89. Saxon A, Max EE, Diaz-Sanchez D, Zhang K. Alternative RNA of epsilon transcripts produces mRNAs encoding two membrane and four secreted IgE isoforms. Int Arch Allergy Immunol 1995;107:45-7.
90. van der Zee JS, Aalberse RC. The role of IgG in immediate-type hypersensitivity. Eur Respir J Suppi 1991;13: 91s -6.
91. Kaneko M, Swanson MC, Gleich 03, Kita H. Allergen- specific IgGl and IgG3 through Fc gamma Rh induce eosinophil degranulation. J Clin Invest 1995;95:2813-21.
92. Leynadier F, Abuaf N, Halpern GM, Murrieta M, GarciaDuarte C, Dry J. Blocking IgG antibodies after rush immunotherapy with mites. Ann Allergy 1986;57:325-9.
93. Witteman AM, Stapel SO, Sjamsoedin DH, Jansen HM, Aalberse RC, van der Zee IS. Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. Int Arch Allergy Immunol 1996; 109:369-75.
94. Star M, Weinstock M. Studies in pollen allergy. III. The relationship between blocking antibody levels, and symptomatic relief following hyposensitization with Ailpyral in hay fever subjects. Tnt Arch Allergy 1970;38:514-21.
95. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom- specific immunoglobulin G antibody level during immunotherapy. I Allergy Clin Immunol 1982;69:489-93.
96. Visco V, Dolecek C, Denepoux S. et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157: 956-62.
97. Djurup R, østerballe 0. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984;39: 433-41.
98. Bousquet 3, Maasch H, Martinot B, Hejjaoui A, WahI R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-46.
99. MUller U, Heibling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honeybee venom. Allergy 1989;44:412-18.
100. Reisman RE. Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? [editorial; comment]. J Allergy Clin Immunol 1992;90:282-4.
101. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:579-87.
102. Djurup R, Mailing H-J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459-68.
103. Ito K, Kudo K, Okudaira H, et al. IgGl antibodies to house dust mite (Dermatophagoides farinae) and late asthmatic response. mt Arch Allergy Appl Immunol 1986;81 :69-74.
104. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21: 115-19.
105. Hedlin 0, Silber 0, Naclerio R, et al. Comparison of the in vivo and in vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990;20:491-500.
106. Durham S, Varney V, Gaga M, Jacobson M, Frew A, Kay A. Grass pollen immunotherapy decreases mast cell numbers in the skin. Proc Am Assoc Phys 1997;submitted.
107. Bousquet 3, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. I Allergy Clin Immunol 1991;88:43-53.
108. Creticos PS, Adkinson N Jr, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76:2247-53.
109. Furin MI, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
110. Iliopoulos 0, Proud D, Adkinson N Jr, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. I Allergy Clin Immunol 1991; 87:855-66.
111. Rak S, Lowhagen 0, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-80.
112. Jutel M, MUller U, Fricker M, Rihs S, Pichier W, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Immunol 1996;12:1112-18.
113. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51 :430-4.
114. Durham S, Varney V, Gaga M, Frew A, Jacobson M, Kay A. Grass pollen immunotherapy remains effective 3 years after discontinuation: a double-blind, placebo- controlled withdrawal study. Clin Exp Allergy 1998; in press.
115. Durham S, Varney V, Gaga M, Frew A, Jacobson M, Kay A. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991;21 Suppl 1:206-10.
116. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late- phase cutaneous responses. I Clin Invest 1993;92:644-51.
117. Durham SR, Ying 5, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4- T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-65.
118. Hamid Q, Schotman E, Jacobson M, Walker S, Durham S. Increases in interleukin-12 (IL-12) messenger RNA+ (mRNA+) cells accompany inhibition of allergen induced late skin responses following successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
119. Renz H, Lack G, Saloga J, et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen- induced sensitization. J Immunol 1994:152:351-60.
120. Jutel M, Pichler WI, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
121. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
122. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-38.
123. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-9.
124. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-47.
125. Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE, Yssel H. Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL- 4 or IL-13. J Immunol 1995;155:4199-4206.
126. Tsicopoulos A, Labalette M, Akoum H, et al. CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy. Clin Exp Allergy 1996;12:1119-25
127. Akdis CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A, in bee venom immunotherapy and recovery by IL-3 and IL-15 in vitro. J Clin Invest 1996;98:1676-83.
128. Osterballe 0. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Allergy 1980;35:473-89.
129. Norman P, Winkenwerder W, Lichtenstein L. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole extracts and placebo. J Allergy 1968;42:93-108.
130. Reisman RE, Wicher K, Arbesman CE. Immunotherapy with antigen E. J Allergy 1969;44:82-95.
131. van Metre TE, Adkinson N Jr, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:288-97.
132. Hirsch SR, Kalbfleisch JH, Golbert TM, et al. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol 1981;68:133-55.
133. Hirsch SR, Kalbfleisch JH, Cohen SH. Comparison of Rinkel injection therapy with standard immunotherapy. J Allergy Clin Immunol 1982;70:183-90.
134. Bousquet J, Des Roches A, Paradis L, Dhivert H, Michel FB. Specific immunotherapy in house dust mite allergy. Clin Rev Allergy Immunol 1995;13:151-9.
135. Turkeltaub PC, Campbell G, Mosimann JE. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy. Allergy 1990;45:528-46.
136. Creticos PS, van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson N Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
137. Haugaard L, Dahl R, Jacobsen L. A controlled doseresponse study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22.
138. Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immuno1 1988;82:360-70.
139. Bousquet J, Michel E Specific immunotherapy in allergic rhinitis and asthma. In: Busse W, Holgate S, editors Asthma and rhinitis. Oxford: Blackwell Scientific
140. Taylor WW, Ohman J Jr, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978;61:283-7.
141. Ohman J Jr, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74:230-9.
142. Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478-87.
143. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992;47:249-54.
144. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody- standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-66.
145. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6
146. Hunt KJ, Sobotka AK, Valentine MD, Yunginger JW, Lichtenstein LM. Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978;61:48-53.
147. Miiller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus whole-body extract. Allergy 1979;34:369-78.
148. Doh I, Martinez-Cbcera C, Bartolomi JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51: 489-500.
149. van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol 1990;86:141-6.
150. Lichtenstein L, Norman P, Winkenwerder L. A single year of immunotherapy in ragweed hay fever. Am J Med 1971;44:514-24
151. Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978;61:370-7
152. Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990;86: 292-305.
153. Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy 1992;47:3-11.
154. Des Roches A, Paradis L, MCnardo J-L, Bouges S, Daurks J-P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99: 450-3.
155. Gillman SA, Cummins LH, Kozak P Jr, Hoffman DR. Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy 1980;45:351-4.
156. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370-4.
157. Mosbech H, Malling H-J, Biering I, et al. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986;41:95-103.
158. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
159. Muller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991;87:702-9.
160. Tarhini H, Knani J, Michel FB, Bousquet J. Safety of venom immunotherapy administered by a cluster schedule. J Allergy Clin Immunol 1992;89:1198-9.
161. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:226-30.
162. van der Zwan JC, Flinterman J, Jankowski IG, Kerckhaert JA. Hyposensitisation to wasp venom in six hours. BMJ 1983;287: 1329-3 1.
163. Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol 1987;79:947-54.
164. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prolonged maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:482-4.
165. Bousquet J, Knani J, Velasquez G, Menardo JL, Guilloux L, Michel FB. Evolution of sensitivity to Hymenoptera venom in 200 allergic patients followed for up to 3 years. J Allergy Clin Immunol 1989;84:944-50.
166. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis J Allergy Clin Immunol 1993;92:831-6.
167. Bousquet J, Michel F. Immunotherapy in rhinitis. In: Mygind N, Naclerio R, editors. Allergic and non-allergic rhinitis; clinical aspects. Copenhagen: Munksgaard, 1992: 136-48.
168. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Doubleblind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:490-7.
169. Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: a controlled trial comparing crude grass pollen extract with the isolated main protein components. Lancet 1954;1:1055-8.
170. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72: 448-53.
171. Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R. A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Imrnunol 1986;78:1180-4.
172. McAllen M. Hyposensitization in grass pollen hay fever. Acta Allergol 1969;24:421-31.
173. Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JM. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp AlIergy 1990;20:653-60.
174. Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JM. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy. Allergy 1991;46:335-48.
175. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebocontrolled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 283-90.
176. Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alumabsorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:281-90.
177. Starr M, Weinstock M. Studies in pollen allergy. 111. The relationship between blocking antibody levels, and symptomatic relief following hyposensitization with Allpyral in hay fever subjects. Int Arch Allergy 1970;38:514-21.
178. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-9.
179. Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy 1981;36:309-17.
180. Arbesman CE, Reisman RE. Hyposensitization therapy including repository: a double-blind study. J Allergy 1964;35:12-17
181. Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R. A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:494-9.
182. Lichtenstein L, Norman P, Winkenwerder W. Clinical and in v i m studies on the role of immunotherapy in ragweed hay fever. Am J Med 1968;44514-24.
183. Lowell F, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965;273:675-9.
184. Meriney DK, Kothari H, Chinoy P, Grieco MH. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:34-8.
185. van Metre TE, Adkinson N Jr, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;66:500-13.
186. van Metre TE, Adkinson N Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69181-93.
187. Norman PS, Lichtenstein LM. Comparisons of alumprecipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1978;61:384-9.
188. Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70: 248-60.
189. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare in patients with respiratory allergy to Purieruriu pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy 1995;25:149-58.
190. Ortolani C, Pastorello EA, Incorvaia C, et al. A doubleblind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Purietaria juduica in patients with Parietaria hay fever. Allergy 1994;49:13-21.
191. Pence H, Mitchell D, Greenly R, Updegraft B, Selfridge H. Immunotherapy for mountain cedar pollinosis. A doubleblind controlled study. J Allergy Clin Immunol 1976;58
192. Karmakar PR, Das A, Chatterjee BF! Placebo-controlled immunotherapy with Cocos nucifera pollen extract. Int Arch Allergy Immunol 1994;103:194-201.39-50.
193. Cantani A, Businco E, Benincori N, de Angelis M, di Fazio A, Businco L. A three year controlled study in children with pollinosis treated with immunotherapy. Ann Allergy 1984;53:79-84.
194. Norman P, Winkenwerder W, Lichtenstein L. Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. J Allergy 1971;47:273-82.
195. Citron K, Frankland A, Sinclair J. Inhalation tests of bronchial hypersensitivity in pollen asthma. Thorax 1958; 13:229-32
196. Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989;63:127-35.
197. Rak S, HakAnsson L, Venge F! Eosinophil chemotactic activity in allergic patients during the birch pollen season: the effect of immunotherapy. Int Arch Allergy Appl Immunol 1987;82:349-50.
198. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590-600.
199. Bruce C, Norman P, Rosenthal R, Lichtenstein L. The role of ragweed pollen in autumnal asthma. J Allergy Clin Immunol 1977;59:449-59.
200. Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grasspollen asthma. BMJ 1982;284306-9.
201. Bousquet J, Hejjaoui A, Becker WM, et al. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. J Allergy Clin Immunol 1991;87:737-46.
202. P h e J, Rivier A, Lagier B, Becker WM, Michel FB, Bousquet J. Differences in IL-4 release by PBMC are related with heterogeneity of atopy. Immunology 1994; 81:58-64
203. Eriksson NE, Wihl Jk, Arrendal H, Strandhede SO. Tree pollen allergy. 111. Cross reactions based on results from skin prick tests and the RAST in hay fever patients. A multi-centre study. Allergy 1987;42:205-14.
204. Hirschwehr R, Valenta R, Ebner C, et al. Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. J Allergy Clin Immunol 1992;90:927-36.
205. Ebner C, Hirschwehr R, Bauer L, et al. Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995; 95:962-9.
206. Pauli G, Bessot JC, Dietemann-Molard A, Braun PA, Thierry R. Celery sensitivity: clinical and immunological correlations with pollen allergy. Clin Allergy 1985;15: 273-9
207. Bernhisel-Broadbent J. Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Ann Allergy Asthma Immunol 1995;75:295-303.
208. Moller C. Effect of pollen immunotherapy on food hyper- sensitivity in children with birch pollinosis. AM Allergy 1989;62:343-5.
209. Kelso JM, Jones RT, Tellez R, Yunginger JW. Oral allergy syndrome successfully treated with pollen immunotherapy. Ann Allergy Asthma Immunol 1995;74:391-6.
210. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994;94: 1-11.
211. McAllen M, Assem E, Maunsell K. House-dust mite asthma. Results of challenge tests on five criteria with Dermatophagoides pteronyssinus. BMJ 1970;2:501-4.
212. Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint-Remy JM. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990;85: 1024-35.
213. van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992;5: 318-22
214. Garcia-Ortega P, Merelo A, Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest 1993;103:183-7.
215. Mosbech H, Dreborg S, Frolund L, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. 11. Effect evaluated by challenges with allergen and histamine. Allergy 1989;44: 499-509
216. D'Souza M, Pepys J, Wells I, et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973;3: 177-93.
217. Gabriel M, Ng H, Allan W, Hill L, Nunn A. Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. Clin Allergy 1977;7:325-36.
218. Amaral-Marques R, Avila R. Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. Allergol Immunopathol (Madr) 1978;6:231-5.
219. Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled study of Alpare mite. D. pteronyssinus immunotherapy in asthmatic patients. Allergo1 Immunopathol (Madr) 1995;23:58-66.
220. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1- year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52:853-9.
221. Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-83.
222. Gaddie J, Skinner C, Palmer K. Hyposensitization with house dust mite vaccine in bronchial asthma. BMJ 1976:21:561-2.
223. Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984;74524-35.
224. Newton D, Maberley D, Wilson R. House dust mite hyposensitization. Br J Dis Chest 1978;72:21-8.
225. Armentia-Medina A, Tapias JA, Martin JF, Ventas F', Fernandez A. Immunotherapy with the storage mite LepidogIyphus destructor. Allergol Immunopathol (Madr) 1995;23:211-23.
226. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. 11. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971-7.
227. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Derrnatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen- specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:521-31.
228. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:501-8.
229. Pastorello EA, Ortolani C, Incorvaia C, et al. A doubleblind study of hyposensitization with an alginateconjugated extract of Dermatophagoides pteronyssinus (Conjuvac) in patients with perennial rhinitis. 11. Immunological aspects. Allergy 1990;45:505-14.
230. Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994;49: 100-7
231. Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Bstergaard PA. Immunotherapy with dog and cat extracts in children. Allergy 1989;44:330-5.
232. Bucur J, Dreborg S, Einarsson R, Ljungstedt-Pahhan I, Nilsson JE, Persson G. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy 1989;62:355-61.
233. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87: 955-64
234. Lilja G, Sundin B, Graff-Lonnevig V, et al. Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 1989;83: 37-44.
235. Rohatgi N, Dunn K, Chai H. Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy. J Allergy Clin Immunol 1988;82389-97.
236. Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986;57: 173-9.
237. Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Irnmunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984;53:85-8.
238. van Metre TE, Marsh DG, Adkinson N Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82:1055-68.
239. Salvaggio J, Aukrust L. Postgraduate course presentations. Mold-induced asthma. J Allergy Clin Immunol 1981; 68:327-46.
240. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized AZternaria extract. J Allergy Clin Immunol 1990;85:460-72.
241. Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarurn. Allergy 1986;41:507-19.
242. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporiurn herbarurn preparation. I. Clinical results. Allergy 1986;41:131-40.
243. Allergenic extracts made from bacteria. Federal Register, 42 FR 58266, 44 FR 1544, 1979.
244. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 199531 1969-74
245. Adkinson NF Jr, Eggleston P, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Eng1 J Med 1997;336:324-31.
246. Mosbech H, Bsterballe 0. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 431523-9
247. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from longterm (6-year) follow-up. Allergy 1997;52:914-20.
248. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;73:484-9
249. Norman PS, Creticos PS, Marsh DG. Frequency of booster injections of allergoids. J Allergy Clin Immunol1990;85: 88-94.
250. Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy 1994;49:38-42
251. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Derrnatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984;14:209-19.
252. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879-85.
253. Yeung M, O'Connor SA, Parry DT, Cochrane GM. Compliance with prescribed drug therapy in asthma. Respir Med 1994;88:31-5.
254. Weinstein AG. Strategies to improve drug compliance in children. Del Med J 1981;53:139-42.
255. Thomas EJ, Burstin HR, O'Neil AC, Orav EJ, Brennan TA. Patient noncompliance with medical advice after the emergency department visit. Ann Emerg Med 1996;27:49-55.
256. Pedersen S. Ensuring compliance in children. Eur Respir J 1992;5:143-5
257. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-7
258. Lower T, Henry J, Mandik L, Janosky J, Friday G Jr. Compliance with allergen immunotherapy. Ann Allergy 1993;70:480-2.
259. Rudd S. Immunotherapy compliance - a shot in the dark. Ann Allergy Asthma Immunol 1995;74:195-8.
260. Tinkelman D, Smith F, Cole WR, Silk HJ. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995;74:241-6.
261. Frost L, Johansen F', Pedersen S, Veien N, Bstergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985;40368-72.
262. Garcia-Patos V, Pujol RM, Alomar A, et al. Persistentsubcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol 1995;131:1421-4
263. Phanuphak P, Kohler PE Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980;68:479-85.
264. Cabrera GE, Citera G, Gutierrez M, Scopelitis E, Espinoza LR. Digital vasculitis following allergic desensitization treatment. J Rheumatol 1993;20:1970-2.
265. Stewart GD, Lockey RE Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 199290567-78
266. Greenberg MA, Kaufman CR, Gonzalez GE, Trusewych ZP, Rosenblatt CD, Summers RJ. Late systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1988;82:287-90.
267. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-3.
268. Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts J Allergy Clin Immunoll992; 89:925-33.
269. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. 111. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797-802.
270. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy 1986;56:331-4.
271. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990 851473-9
272. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994;73:409-18.
273. Jarisch R, Gotz M, Aberer W, et al. Reduction of side effects of specific imrnunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50000 SQ-U/ml. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1988;82:163-75.
274. Nielsen L, Johnsen C, Mosbech H, Poulsen L, Malling H. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:1207-13.
275. Berchtold E, Maibach R, Miiller U. Reduction of side effects from rush-immunotherapy with honeybee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 2259-65.
276. Bsterballe 0. Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982;37:553-62.
277. Lessof M, Chandler B. Experience with Spectralgen®/ Pharmalgen? a new kind of allergen preparation. Amsterdam: Excerpta Medica, 1983.
278. Lockey RF, nrkeltaub PC, Olive ES, Hubbard JM, Baird- Warren IA, Bukantz SC. The Hymenoptera venom study. 111. Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80.
279. Miiller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigne R. A double blind study on immunotherapy with chemically modified honeybee venom: monomethoxy polyethylene glycol-coupled versus crude honeybee venom. Int Arch Allergy Appl Immunol 1985;77:201-3.
280. Nataf P, Guinnepain MT, Herman D. Rush venom immunotherapy: a 3-day programme for Hymenoptera sting allergy. Clin Allergy 1984;14:269-75.
281. Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. Clinical and immunologic studies of rapid venom immunotherapy in Hymenopterasensitive patients. J Allergy Clin Immunol 1989;84:951-9.
282. Malling H-J, Djurup R, Sondergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy 1985;40:373-83.
283. Bousquet J, Demoly P, Michel FB. Specific imrnuno- therapy. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Philadelphia: Lippincott-Raven, 1997:1667-8
284. Committee on Safety of Medicines. Desensitizing vaccines. BMJ 1986;293:948.
285. Lockey W, Benedict LM, Tbrkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77.
286. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993;926-15.
287. Reid M, Lockey R, Turkeltaub R, Platts-Mills TAE. Fatalities (F) from immunotherapy (IT), 1990-91 [abstract]. J Allergy Clin Immunol 1992;89:100. 1997~1667-82
288. Turkeltaub I? FDA Medical Bulletin 1994;7:May
289. Liideritz-Piichel U, May S, Haustein D. Zwischenfalle nach Hyposensibilisierung. Munch Med Wochenschr 1996;138: 129-32.
290. Norman PS. Safety of allergen immunotherapy. J Allergy Clin Immunol 1989;84:438-9.
291. American Academy of Allergy and Immunology. The waiting period after allergen skin testing and immunotherapy. J Allergy Clin Immunol 1990;85:526-7.
292. Miiller U, Mosbech H, Blaauw P, et al. Emergency treatment of allergic reactions to Hymenoptera stings. Clin Exp Allergy 1991;21:281-8.
293. Miiller U, Mosbech H, Aberer W, et al. Adrenaline for emergency kits. Allergy 1995;50:783-7.
294. Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters (American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, the Joint Council of Allergy, Asthma, and Immunology). J Allergy Clin Immunol 1996;98:1001-11.
295. Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14541-50.
296. Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients An efficacy study in oral hyposensitization. Allergy 1985;40:321-35.
297. Mosbech H, Dreborg S, Madsen F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 1987;42:451-5.
298. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral imrnunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:61-7.
299. Moller C, Dreborg S, Lanner A, Bjorkstbn B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986; 411271-9
300. Giovane AL, Bardare M, Passalacqua G, et al. A threeyear double-blind placebo-controlled study with specific ral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:53-9.
301. Taudorf E, Laursen LC, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80:153
302. Scadding G, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:493-9.
303. Reilly D, Taylor M, Beattie N, et al. Is evidence for homeopathy reproducible? Lancet 1994;344:1601-6.
304. van Niekerk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever: a double-blind study. Clin Allergy 1987;17:507-13.
305. Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr) 1993;21:173-8.
306. Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4:305-14.
307. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio P€? Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23:224-30.
308. Sabbah A, Hassoun S, Le Sellin J, AndrB C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
309. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18:277-84.
310. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5:25-30.
311. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229-36.
312. Georgitis JW, Nickelsen JA, Wypych JI, Kane JH, Reisman RE. Local nasal immunotherapy: efficacy of lowdose aqueous ragweed extract. J Allergy Clin Immunol 1985;75:496-500
313. Georgitis JW, Nickelsen JA, Wypych JI, Barde SH, Clayton WF, Reisman RE. Local intranasal immunotherapy with high-dose polymerized ragweed extract. Int Arch Allergy Appl Immunol 1986;81:170-3.
314. Welsh PW, Butterfield JH, Yunginger JW, Agarwal MK, Gleich GJ. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983;71:454-60.
315. Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani €? Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. J Investig Allergol Clin Immunol 1995;5:126-32.
316. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 1992;47:318-23.
317. Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal immunotherapy for Dermatophagoides- induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993;91:987-96.
318. Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:1092-9.
319. Andri L, Senna G, Betteli C, et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol 1996;97:34-41.
320. Bardare M, Zani G, Novembre E, Vierucci A. Local nasal immunotherapy with a powdered extract for grass pollen induced rhinitis in pediatric age. J Investig Allergol Clin Immunol 1996;6:359-63.
321. Cirla AM, Sforza N, Roffi GP, et al. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis A doubleblind study. Allergy 1996;51:299-306.
322. D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:141-8.
323. Georgitis JW, Reisman RE, Clayton WF, Muller UR, Wypych JI, Arbesman CE. Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 1983;71:71-6.
324. Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984;74:694-700.
325. Johansson SG, Deuschl H, Zetterstrom 0. Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitization treatment of hay fever. Int Arch Allergy Appl Immunol 1979;60:447-60.
326. Nickelsen JA, Goldstein S, Muller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis. 11. Immunologic response. J Allergy Clin Immunol 1981;68:41-5.
327. Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Purietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med 1995; 1521461-6.
328. Schumacher MJ, Pain MC. Intranasal immunotherapy and polymerized grass pollen allergens. Allergy 1982;37: 241-8.
329. Welsh PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol 1981 ;67:237-42
330. BjorkstCn B. Local immunotherapy is not documented for clinical use. Allergy 1994;49299-301.
331. Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Imm~n01 1991;87:721-8.
332. Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma - a double-blind study. J Investig Allergol Clin Immunol 1992;2:59-67.
333. Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 1994;94:662-5.
334. Jacobsen L. The benefit of specific allergy treatment. In: Basomba A, Sastre J, editors Proceedings of the XVI European Congress of Allergology and Clinical Immunology. Bologna, Italy: Monduzzi Editore, 1995:745-50.
335. Jacobsen L, Dreborg S, MQller C, et al. Immunotherapy as a preventive treatment [Abstract]. J Allergy Clin Immunol 1996;97:232.
336. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Michel F. Specific immunotherapy prevents the onset of new sensitizations in monosensitized children [Abstract]. J Allergy Clin Immunol 1995;95:309.
337. Barnard J. Studies of 400 Hymenoptera sting deaths. J Allergy Clin Immunol 1973;52:259-64.
338. Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 1994;94662-5.
339. Perrin JM, MacLean W Jr, Perrin EC. Parental perceptions of health status and psychologic adjustment of children with asthma. Pediatrics 1989;83:26-30.
340. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:256-62.
341. Sampson HA. Food allergy and the role of immunotherapy. J Allergy C l i Immunol 1992;90:151-2.
342. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-6.
343. Leroy B, Lachapelle JM, Jacquemin MG, Saint-Remy JM. Immunotherapy of atopic dermatitis by injections of antigen- antibody complexes. Dermatology 1993;186:276-7.
344. Kaplan Ap, Anderson JA, Valentine MD, et al. Betaadrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology. J Allergy Clin Imm~n011 989;84:129-30
345. Schwartz HJ, Golden DB, Lockey RE Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990;85:709-12.
346. Schumacher MJ, Tveten MS, Egen NB. Rate and quantity of delivery of venom from honeybee stings. J Allergy Clin Immunol 1 994;93: 83 1-5.
347. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620-4.
348. Reisman RE, Livingston A. Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses. J Allergy Clin Immunol 1992;89:1189-95.
349. Bousquet J, Menardo JL, Aznar R, Robinet-Levy M, Michel FB. Clinical and immunologic survey in beekeepers in relation to their sensitization. J Allergy Clin Immunol 1984;73:332-40.
350. Bousquet J, Menardo JL, Velasquez G, Michel FB. Systemic reactions during maintenance immunotherapy with honeybee venom. Ann Allergy 1988;61:63-8.
351. Kampelmacher MJ, van der Zwan JC. Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspects. Clin Allergy 1987;17: 317-27
352. van Halteren HK, van der Linden PW, Burgers SA, Bartelink AK. Hymenoptera sting challenge of 348 patients: relation to subsequent field stings. J Allergy Clin Immunol 1996;97:1058-63.
353. Blaauw PJ, Smithuis OL, Elbers AR. The value of an inhospital insect sting challenge as a criterion for application or omission of venom immunotherapy. J Allergy Clin Immunol 1996;98:39-47.
354. Franken HH, Dubois AE, Minkema HJ, van der Heide S, de Monchy JG. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol 1994;93:431-6.
355. Rueff F, Przybilla B, Miiller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom of the European Academy of Allergology and Clinical Immunology. Allergy 1996;51:216-25.
356. Nordvall SL, Johansson SG, Ledford DK, Lockey RE Allergens of the imported fire ant. J Allergy Clin Immunol 1988;82:567-76
357. Norman P. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996; 154: 1225-8.
358. Barnes l? Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996;154:1227-8.
359. Bousquet J, Dhivert H, Michel FB. Current trends in the management of allergic diseases. Allergy 1994;4931-6.
360. Bush R, Huftel M, Busse W. Patient selection. In. Lockey R, Bukantz S, editors. Allergen immunotherapy. New York: Marcel Dekker, 1991:25-49.
361. Platts-Mills TAE, Vervloet D, Thomas W, Aalberse R, Chapman M. Report of the Third International Workshop on Indoor Allergens and Asthma. J Allergy Clin Immunol 1998;1OO:Sl-S25
362. Reed CE, Yunginger JW, Evans R. Quality assurance and standardization of allergy extracts in allergy practice. J Allergy Clin Immunol 1989;844-8.
363. Position paper on allergen immunotherapy. Report of a BSACI working party. January-October 1992. Clin Exp Allergy 1993;3:1-44.
364. Munir AKM, BjorkstCn B, Einarsson R, et al. Cat (Pel d I), dog (Can f I), and cockroach allergens in homes of asthmatic children from three climatic zones in Sweden. Allergy 1994;49:508-16.
365. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6
366. Adelroth E, Rosenhall L, Glennow C. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. A two-year study. Allergy 1985;40:58-64.
367. Rutten van Molken MP, van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FE Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 15 1 :975-82.
368. Weiss K. The impact of pharmacologic therapy on the costs of asthma. Allergy Proc 1994;15:189-92.
369. Hughes DM, McLeod M, Garner B, Goldbloom RB. Controlled trial of a home and ambulatory program for asthmatic children. Pediatrics 1991;87:54-61.
370. Mayo PH, Richman J, Harris HW. Results of a program to reduce admissions for adult asthma. Ann Intern Med 1990;112:864-71
371. Ross RN, Morris M, Sakowitz SR, Berman BA. Costeffectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clin Ther 1988;10188-203.
372. Mahr TA, Evans RD. Allergist influence on asthma care. Ann Allergy 1993;71:115-20.
373. Doan T, Grammer LC, Yarnold PR, Greenberger PA, Patterson R. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Ann Allergy Asthma Immunol 1996;76513-18.
374. Storms B, Olden L, Nathan R, Bodman S. Effect of allergy specialist care on the quality of life in patients with asthma. Ann Allergy Asthma Immunol 1995;75:491-4.
375. Sullivan T, Selner J, Patterson R, Portnoy J, Seligmanqh M. Expert care and immunotherapy for asthma. A review of published studies with emphasis on patient outcome and cost. American College of Allergy, Asthma, and Immunology, 1996.
376. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immuno1 1994;94:182-8.
377. Liblau RS, Singer SM, McDevitt HO. Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
378. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99.
379. Lenschow DJ, Walunas TL, Bluestone JA. CD28B7 system of T cell costimulation. Annu Rev Immunol 1996; 14233-58.
380. Kuchroo VK, Das Mp, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Thl/ Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80707-18.
381. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J Exp Med 1996;183:1613-21.
382. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:2054-7.
383. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996;2741707-9.
384. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-4.
385. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type I1 collagen on rheumatoid arthritis. Science 1993;261:1727-30.
386. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993; 341:927-8.
387. Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995;7:751-6
388. Anderson P. Delivery systems for immunomodulatory proteins and peptides. BioDrugs 1997;7:51-65.
389. McWilliam AS, Stewart GA. Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens. Potential adjuvants in the immunotherapy of allergic disease. J Immunol Methods 1989;121:53-60
390. Ferreira F, Hirthenlehner K, Briza P, et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997;113:125-7
391. Ferreira F, Hirtenlehner K, Jilek A, et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599-609
392. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996;33:399-405.
393. Noguchi E, Shibasaki M, Nishiyama C, Okumura Y, Takita H. IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f 1, Der f 2 and mutant proteins of Der f 2. Int Arch Allergy Immunol 1996; 110:380-7.
394. Vrtala S, Hirtenlehner K, Vangelista L, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments; candidates for a novel form of irnmunotherapy. J Clin Invest 1997;99:1673-81.
395. Yssel H, Fasler S, Lamb J, de Vries JE. Induction of nonresponsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol 1994;6:847-52.
396. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A 1993; 90:7608-12
397. Hoyne GF, Callow MG, Kuo MC, Thomas WR. Characterization of T-cell responses to the house dust mite allergen Der p I1 in mice. Evidence for major and cryptic epitopes. Immunology 1993;78:65-73.
398. Norman P, Ohman J Jr, Long A, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
399. Ball T, Vrtala S, Sperr WR, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269:28323-8.
400. Gajhede M, Osmark P, Poulsen F, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996;3:1040-4.
401. Fedorov A, Ball T, Mahoney N, Valenta R, Almo S. Crystal structure and IgE-epitope mapping of birch pollen profilin: molecular basis for allergen cross-reactivity. Structure 1997;15:33-45.
402. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997;60:163-72.
403. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995;17:79-83.
404. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Tnl immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 1996;93:5141-5.
405. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2:540-4.
406. Lichtenstein L, Holtzman N, Burnett L. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:317-24.
407. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130:721-6
408. Birkner T, Rumpold H, Jarolim E, et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy 1990;45:418-26.
409. Menz G, Dolecek C, Schonheit-Kenn U, et al. Serological and skin-test diagnosis of birch pollen allergy with recornbinant Bet v 1, the major birch pollen allergen. Clin Exp Allergy 1996;26:50-60.
410. Pauli G, Oster JP, Deviller P, et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin lmmunol 1996;97:1100-9.
411. Vrtala S, Susani M, Sperr WR, et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5 ) . J Allergy Clin Immunol 1996;97:781-7.
412. Tame A, Sakiyama Y, Kobayashi I, Terai I, Kobayashi K. Differences in titres of IgE, IgG4 and other IgG subclass anti-Der p 2 antibodies in allergic and non-allergic patients measured with recombinant allergen. Clin Exp Allergy 1996;26:43-9.
413. Kobayashi I, Sakiyama Y, Tame A, Kobayashi K, Matsumoto S. IgE and IgG4 antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group I1 antigen (Der p 2). J Allergy Clin Immunol 1996;97:638-45.
414. Lebecque S, Dolecek C, Laffler S, et al. Immunologic characterization of monoclonal antibodies which modulate human immunoglobulin E binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997;99: 374-84
415. Vassella CC, Odelram H, Kjellman NI, Borres MP, Vanto T, BjorkstCn B. High anti-IgE levels at birth are associated with a reduced allergy prevalence in infants at risk: a prospective study. Clin Exp Allergy 1994; 24:771-7.
416. Miescher S, Vogel M, Stampfli MR, et al. Domain-specific anti-IgE antibodies interfere with IgE binding to Fc epsilon RII. Int Arch Allergy Immunol 1994;105:75-82.
417. Shakib F, Smith SJ. In vitro basophil histamine-releasing activity of circulating IgGl and IgG4 autoanti-IgE antibodies from asthma patients and the demonstration that anti-IgE modulates allergen-induced basophil activation. Clin Exp Allergy 1994;24270-5.
418. F'resta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:26368-73.
419. Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
420. Demoly P, Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997;155:1825-7.
421. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Irnmunol 1994;24:415-20.
422. Stadler B, Rudolf M, Vogel M, Mieser S, Ziircher A, Kricek F. Can active immunization redirect an anti-IgE immune response? Int Arch Allergy Immunol 1997;113: 216-18.